The “Retinoblastoma Treatment Market” research report 2019-2024 delivers comprehensive information and valuable insights about the Retinoblastoma Treatment industry. The information available in the Retinoblastoma Treatment market report is not only based on the facts but also on the case studies, which analysts have included to convey appropriate information to the clients in a well-versed manner. Retinoblastoma Treatment market report includes valuable information to assist new entrants, as well as established players, to understand the prevailing trends in the market.
Some Companies Are Covered in the Retinoblastoma Treatment Market:
Get a Sample Copy of the Report – https://www.industryresearch.co/enquiry/request-sample/13999710
Scope of the Report:
Reasons for Buying Retinoblastoma Treatment Market Report:
- This report provides pin-point analysis for changing competitive dynamics
- It provides a forward looking perspective on different factors driving or restraining market growth
- It provides a five-year forecast assessed on the basis of how the market is predicted to grow
- It helps in understanding the key product segments and their future
- It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
- It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments
For More Information or Query or Customization Before Buying, Visit at – https://www.industryresearch.co/enquiry/pre-order-enquiry/13999710
Key Market Trends:
Non-hereditary Retinoblastoma is Expected to hold its Highest Market Share in the Retinoblastoma Type Segment
In the Retinoblastoma type segment of the Retinoblastoma treatment market, the non-hereditary retinoblastoma (NHR) is expected to have the largest market size and is likely to witness a CAGR of 3.82% in the forecast period.
Non-hereditary retinoblastoma (NHR), also known as sporadic retinoblastoma, is the more prevalent form of retinoblastoma. According to the American Cancer Society, 67% of reported cases (in the United States) of retinoblastoma in pediatrics are non-hereditary or sporadic.
The NHR is mostly a pediatric disease, and according to the American Cancer Society, the survival rates post diagnosis is approximately 90%. According to the Union for International Cancer Control, the average age-adjusted incidence rate of retinoblastoma in the United States and Europe is 2-5/106 children (approximately one in 14,000 18,000 live births).
The market for NHR is expected to grow tremendously over the forecast period, primarily due to the higher incidence rate, when compared to hereditary retinoblastoma. Additionally, factors, like high survival rates post diagnosis in developed regions, like the United States, are likely to add to the global market growth.
Asia-Pacific Dominates the Market and Expected to do Same in the Forecast Period
Asia-Pacific currently dominates the market for Retinoblastoma Treatment and is expected to continue its strong hold for a few more years. This region is expected to increase its market share in the future owing to the fact that, retinoblastoma (Rb) is the most common primary intraocular malignancy of infancy and childhood, and seriously endangers the vision and life of children.
According to the United Nations Survey in 2016, China was only second to that in India, in the prevalence of Rb in APAC countries. Similarly, according to the Japanese Journal of Ophthalmology, in 2018, the average occurrence frequency for retinoblastoma was 1:16,823 births/year and at diagnosis, 89.0% of the patients were aged younger than 3 years and 41.0% were aged younger than 1 year.
Furthermore, in countries like India, current treatment modalities of systemic chemotherapy and focal treatment have contributed significantly to disability limitation and patient survival and there is less knowledge on the genetics of the retinoblastoma gene and its protein, and there is potential for developing targeted molecular therapies.
Retinoblastoma Treatment Market Report Provides Comprehensive Analysis of:
- Functional market industry outline
- Up and downstream industry examination
- Channels and propositions believability
- Market challenge by key players
- Enhancement suggestions examination
Purchase this Report (Price 4250 USD for single user license) – https://www.industryresearch.co/purchase/13999710
- Market Dynamics – Drivers, Restraints, and Opportunities
- Market Segmentation – Types, Applications, Regions, and Technology
- Market Trends
- Competitive Landscape
- SWOT Analysis and Porter’s Five Forces Analysis
Detailed TOC of Retinoblastoma Treatment Market Report 2019-2024:
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Remission and the Chance of Recurrence
4.2.2 Increasing Public Awareness
4.3 Market Restraints
4.3.1 Small Patient Pool
4.3.2 Side Effects of Retinoblastoma Surgery
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Treatment Type
5.1.2 Radiation therapy
5.1.3 Laser Therapy (Photocoagulation)
5.1.7 Opthalmic Artery Infusion Chemotherapy
5.1.8 High-dose Chemotherapy and Stem Cell Transplant
5.2 By Type of Retinoblastoma
5.2.1 Non-hereditary Retinoblastoma
5.2.2 Hereditary Retinoblastoma
5.3 By Type of Staging
5.3.1 Intraocular Retinoblastoma
5.3.2 Extraocular Retinoblastoma
5.4.1 North America
126.96.36.199 Rest of Europe
5.4.3 Asia Pacific
188.8.131.52 South Korea
184.108.40.206 Rest of Asia-Pacific
5.4.4 Middle East and Africa
220.127.116.11 South Africa
18.104.22.168 Rest of Middle East and Africa
5.4.5 South America
22.214.171.124 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Baxter International Inc.
6.1.2 Bristol-Myers Squibb Company
6.1.3 Cadila Pharmaceuticals
6.1.4 GlaxoSmithKline plc
6.1.5 Johnson & Johnson
6.1.6 Merck & Co.
6.1.7 Novartis AG
6.1.8 Pfizer Inc.
6.1.9 Teva Pharmaceutical Industries Ltd.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Name: Ajay More
Phone: US +14242530807/ UK +44 20 3239 8187
Email: [email protected]
Our Other Reports: